Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 51 clinical trials
Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia

Hyperkalemia is a common electrolyte disorder, especially among patients with chronic kidney disease, diabetes mellitus, or heart failure. Globally, the reported incidence of hyperkalemia varies from 1.1 to 10 per 100 hospitalizations, depending on the patient cohort and comorbidities. Hyperkalemia is a potentially life-threatening electrolyte disturbance that can be fatal …

  • 03 Feb, 2021
  • 15 locations
Senicapoc and Dehydrated Stomatocytosis

Dehydrated stomatocytosis is a genetic disorder characterized by chronic hemolysis, variable anemia and erythrocyte dehydration. Causative mutations have been identified in either the Gardos

  • 25 Apr, 2021
  • 1 location
Intravenous Gammaglobulin for Sickle Cell Pain Crises

The purpose of this study is to determine whether intravenous immune globulin is safe and effective in the acute treatment of pain crises in sickle cell disease.

  • 07 Nov, 2020
  • 1 location
Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study

The purpose of this study is to establish the safety and feasibility of the Edwards SAPIEN 3 valve in subjects with mitral annular calcification (MAC) associated with mitral stenosis (MS) and/or mitral regurgitation who are at high-risk for mitral valve surgery or deemed inoperable due to the extent of calcification.

  • 02 Feb, 2021
  • 7 locations
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

  • 22 Jan, 2021
  • 5 locations
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who have clinically evident EVH.

  • 09 Mar, 2021
  • 17 locations
A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

evidence of ongoing hemolysis that requires treatment intervention.

  • 25 Jan, 2021
  • 25 locations
A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

: To assess, in participants with cold agglutinin disease, after a single dose of intravenous (IV) BIVV020: The effect of BIVV020 on complement mediated hemolysis

  • 01 Apr, 2021
  • 14 locations
Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in treatment nave patients, patients currently treated with eculizumab who still experience anemia and reticulocytosis and in patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, participants will have periodic …

neutrophil count
platelet count
  • 05 May, 2021
  • 8 locations
A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness

There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the …

  • 24 Jan, 2021
  • 3 locations